YuanSi Biologics

Syneron Bio (also known as YuanSi Biologics or YuanSi Peptide) is a biotechnology company dedicated to developing next-generation macrocyclic peptide therapeutics. Founded in 2022, the company leverages its proprietary Synova™ platform, an intelligent, high-throughput discovery engine that combines artificial intelligence, data science, and high-throughput screening to design, screen, and optimize peptide drugs. This platform aims to bridge the gap between small molecules and biologics, targeting traditionally difficult-to-drug pathways. Syneron Bio is building a diversified pipeline focused on oncology and chronic diseases, including autoimmune, metabolic, and rare conditions. The company has established a major strategic collaboration with AstraZeneca worth up to $3.4 billion to develop novel macrocyclic peptide therapies.